ArticleMMWR. Morbidity and mortality weekly report2024

Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, September 2023-January 2024.

Ruth Link-Gelles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.